ArticleFrontiers in medicine2026
Clinical impact of early enteral nutrition support on gastrointestinal function, nutritional status, liver function, and immune function in liver cancer patients.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This randomized controlled trial aimed to evaluate the clinical impact of early enteral nutrition (EEN) on postoperative gastrointestinal function, nutritional status, liver function, and immune function in primary liver cancer patients. Methods: A total of 80 patients treated between December 2022 and December 2023 were randomly assigned to two groups: experimental group (EEN, Results: The EEN group showed faster recovery in liquid diet intake, bowel movements, and defecation times (all Conclusion: In this randomized controlled trial, early enteral nutrition support significantly improved postoperative gastrointestinal recovery, enhanced nutritional and liver function parameters, boosted immune markers, and shortened hospital stay compared to total parenteral nutrition, with fewer adverse reactions. These findings support the clinical use of EEN in patients undergoing liver cancer surgery. Larger multicenter trials are warranted to confirm the effects on infection rates, liver failure, and long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.